Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
NCT00262730Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2006
- Primary completion
- Aug 2009
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of poly iclc in glioblastoma multiforme (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Overall Survival at 30 months. Started Jan 2006; status: completed.
02
Drugs
poly iclc
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00262730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262730.